Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Added: 8 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
Managing Obesity in HF: 2025 ACC Scientific Statement
Author(s): Michelle Kittleson Added: 9 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific… View more

Cardiovascular Kidney Metabolic

Heart Failure
Research Area(s) / Expertise: Job title: Professor of Medicine
Dr Eileen O’Meara is Professor at the Department of Medicine at the University of Montrealand practices cardiology at the Montreal Heart Institute. Dr O’Meara pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris. Her research focuses on… View more
Author(s): Chim C Lang Added: 10 months ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more

Cardiovascular Kidney Metabolic
Milton Packer
Research Area(s) / Expertise: Job title: Distinguished Scholar in Cardiovascular Science
Personal History Dr Milton Packer was born to Polish immigrants in 1951 and raised in Philadelphia, US. Prior to studying medicine, he was politically active in the 1960s. In his words: “The focus of my upbringing was education, but the major guiding principle in my childhood years (and throughout my entire life) was an uncompromising sense of justice. I was always imbued with the need to… View more
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 6 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Metabolic Factors Now Key Drivers of Heart Failure
Added: 3 months ago Source:  Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from… View more

MI/ACS

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial
Author(s): Harriette Van Spall , Stephen Nicholls Added: 5 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology
Author(s): Chim C Lang , Bianca Rocca , Samira Bell Added: 7 months ago
In this short discussion, join Prof Chim Lang (University of Dundee, Dundee, UK), Guest Editor of the upcoming Special Focus on Obesity in Focus, Prof Bianca Rocca (LUM University, Casamassima, IT) and Dr Samira Bell (University of Dundee, Dundee, UK) to discover the implications of obesity on heart failure, kidney disease, and pharmacology.This conversation sets the stage for the upcoming… View more

Cardiovascular Kidney Metabolic

Heart Failure
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Added: 1 year ago Source:  ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09… View more

Vascular Disease and Surgery

Heart Failure